Biotechnology

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

Anixa Biosciences secures a key Canadian patent for its novel ovarian cancer vaccine, advancing a new paradigm in cancer prevention for high-risk women.

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

Facing a severe cash crunch, Jasper Therapeutics is exploring a sale or even a shutdown, placing the future of its promising urticaria drug, briquilimab, in limbo.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

Biotech firm Kimera Labs implements a unified quality system for its exosome therapies and cosmetics, raising the bar in a complex regulatory landscape.

With over 7 million Americans facing Alzheimer's, an innovative online study empowers you to monitor your brain health and join the fight from home.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.

Gene Solutions' SPOT-MAS 10 test gains FDA Breakthrough Designation, accelerating its path to the U.S. market and heralding a new era in early cancer detection.

New preclinical data shows Sharp Therapeutics' oral drug candidate could reverse key pathologies of the fatal genetic disorder, offering hope beyond symptom management.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

A new service from Syncell offers researchers an unprecedented, unbiased view of proteins at the nanoscopic level, aiming to find drug targets hidden in plain sight.

With a new CMO who has a drug approval under his belt, ImmunoGenesis is poised to advance its novel therapy for hard-to-treat 'cold' tumors.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

Clymb Clinical's new Data Mapper uses AI to automate complex data mapping, promising to accelerate drug trials and redefine statistical programming roles.

PeproMene Bio’s PMB-CT01 offers new hope, achieving a 78% complete response rate with a remarkable safety profile in hard-to-treat lymphoma patients.

A new clinical trial is testing a therapy that treats donor kidneys before transplant, aiming to prevent a common virus that complicates 30% of cases.

ZYUS secures high-interest debt to stay afloat, but a trading halt and unresolved accounting issues raise serious questions about its long-term resilience.